Bamco Inc. NY Acquires Shares of 10,238 Natera, Inc. $NTRA

Bamco Inc. NY purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,238 shares of the medical research company's stock, valued at approximately $2,779,000.

A number of other hedge funds have also added to or reduced their stakes in NTRA. Trust Co. of Vermont bought a new stake in Natera during the second quarter valued at $26,000. Elevation Wealth Partners LLC purchased a new stake in Natera during the second quarter valued at about $30,000. Reflection Asset Management purchased a new stake in Natera during the fourth quarter valued at about $29,000. Rakuten Securities Inc. bought a new stake in Natera during the second quarter worth about $35,000. Finally, Palladiem LLC bought a new stake in Natera during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Trading Up 0.1%

NTRA stock opened at $338.70 on Friday. The stock has a market capitalization of $48.82 billion, a PE ratio of -249.04 and a beta of 1.51. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18. The stock's 50 day simple moving average is $283.17 and its 200 day simple moving average is $232.96.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the firm earned ($0.74) EPS. Natera's revenue was up 37.7% on a year-over-year basis. On average, research analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 295 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the sale, the insider directly owned 183,774 shares in the company, valued at $49,249,594.26. The trade was a 0.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the company's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16. Following the sale, the chief financial officer directly owned 51,637 shares of the company's stock, valued at $14,159,898.14. The trade was a 0.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 177,955 shares of company stock valued at $40,704,193. 5.05% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on NTRA shares. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday, June 5th. They set a "neutral" rating and a $245.00 price target on the stock. Zacks Research raised Natera from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Wall Street Zen cut shares of Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Robert W. Baird set a $348.00 price objective on shares of Natera in a report on Friday, August 7th. Finally, Evercore restated an "outperform" rating and issued a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source